Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.73 |
| ▸ | HTR2B | P41595 | 19/20 | 0.73 |
| ▸ | HTR2A | P28223 | 14/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312109 | 0.95 | HTR2C (0.77) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL6304067 | 0.85 | HTR2C (0.76) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL5362236 | 0.83 | HTR2C (0.66) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL23709316 | 0.83 | RAB9A (0.69) | NPC1RAB9A | |
| SCHEMBL6304598 | 0.83 | HTR2C (0.78) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL6305003 | 0.83 | HTR2C (0.61) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL5368515 | 0.81 | HTR2C (0.89) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL6305416 | 0.79 | HTR2C (0.55) | HTR2CHTR2BHTR2ANPC1RAB9A | |
| SCHEMBL5362705 | 0.79 | HTR2C (0.60) | HTR2CHTR2BHTR2ANPC1MTOR | |
| SCHEMBL6307814 | 0.79 | HTR2C (0.55) | HTR2CHTR2BHTR2ANPC1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | claimed |
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PHARMACIA & UPJOHN COMPANY | 2003-09-25 | — | — | US | claimed |
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291738-B2 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1485386-A2 | PYRIDINYLOXY DERIVATIVES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PHARMACIA & UPJOHN COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003076426-A2 | PYRIDINYLOXY DERIVATIVES AS 5-HT RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181485-A1 | A (2-methyl-3-pyridinyl)oxy)-3-pyridinyl)urea derivatives for treatment of a disease or disorder of the central nervous system, medical diagnosis | PMP22, TPMT, PNPO | HTR2C 180/4885HTR2B 922/4885HTR2A 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.